Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPRG.L Regulatory News (PRG)

  • There is currently no data for PRG

Non-Board Appointments

9 May 2005 07:01

Premier Research Group09 May 2005 For Immediate Release 9 May 2005 Premier Research appoints Anthony Orlando and Bruce C Stouch to New Senior Management Positions Premier Research Group plc (AIM: PRG) ("Premier Research", "Company" or "Group"), the international pharmaceutical services group today announces theappointment of -- Anthony Orlando, Ph.D and Bruce C Stouch Ph.D to seniormanagement positions in Premier Research. Dr Anthony Orlando, Ph.D has joined the US Operations of Premier Research Groupplc in the new position of Executive Director, Data Operations. Dr. Orlandobrings an exceptional background in Biostatistics and Data Management over thepast thirty years including key roles in pharmaceutical companies, the NationalCenter for Toxicological Research/FDA and at major contract researchorganizations. He most recently joined the company from his position as VicePresident, Biostatistics at SFBC New Drug Services. Dr. Orlando holds a Ph.D. inBiometry from Yale University, has co-authored many papers in his area ofexpertise and has supported several drug NDAs for a variety of indications. Hewill be responsible for US data management, programming and biostatistics forPremier Research. In addition to Dr. Orlando's position, Premier Research also is pleased toannounce that Bruce C. Stouch, Ph.D. has taken the international position ofChief Scientific Officer for the company. In Dr. Stouch's new role, he will leadthe company's efforts supporting expert FDA/statistical clinical design andanalysis capabilities. He will also establish and expand the company's newinitiative into Bayesian monitoring and analysis methods. Dr. Stouch has over15 years of biostatistics experience in pharmaceuticals. For 12 years, Dr. Stouch held position of Director of Biostatistics andScientific Data Management at Johnson & Johnson in Exton, PA, where he wasresponsible for strategic development and implementation of pharmacoeconomicmodels of emerging technologies in several therapeutic areas. Dr. Stouch hasbeen involved in over two dozen publications and acknowledgements. He holds anacademic appointment at the Philadelphia College of Medicine as Director,Biostatistics and Clinical Epidemiology. Dr. Stouch received his Ph.D. inBiostatistics and Epidemiology from Jefferson Medical College in 1997 through aprogram sponsored by Johnson & Johnson, and trained in post-graduate studiesfrom Temple University, Jefferson Medical College, and Harvard School of PublicHealth. Dr Simon Yaxley, CEO of Premier Research Group plc, commented: "We are proud andpleased to announce the significant strengthening of our data management andstatistics capabilities in the US Operations, we also believe that Tony andBruce place our company at the forefront of trial design, monitoring andanalysis methods worldwide." About Premier Research Premier Research Group plc is a contract research organisation focused on thedesign, management and reporting of all phases of clinical trials on behalf ofpharmaceutical and biotechnology companies. The Company specialises in oncology,central nervous system, paediatrics and anti-infectives. For Further information, please contact: Premier Research Group Plc Tel: 01344 458 311Dr Simon Yaxley, Chief Executive Buchanan Communications Tel: 020 7466 5000Lisa Baderoon/Diane Stewart/Rebecca Skye Dietrich This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
9th May 201111:26 amRNSDirector/PDMR Shareholding
6th May 20117:00 amRNSOperational update
4th May 20117:00 amRNSDirector/PDMR Shareholding
21st Apr 20117:00 amRNSConditional Acquisition of IDC by Paragon Diamonds
21st Apr 20117:00 amRNSConditional Acquisition of IDC
25th Mar 20119:45 amRNSOperational Update
25th Mar 20117:45 amRNSOperational Update
25th Mar 20117:00 amRNSFinal Results
24th Mar 20117:00 amRNSChange of Registered Office
18th Mar 20117:00 amRNSAppointment of joint broker
1st Feb 20113:52 pmRNSHolding(s) in Company
31st Jan 20117:00 amRNSMabuki Project Update
27th Jan 20117:00 amRNSIssue of Equity
10th Jan 20117:00 amRNSDirector/PDMR Shareholding
6th Jan 20117:00 amRNSLicence Award
29th Dec 20109:43 amRNSNotification of Interest
22nd Dec 20107:00 amRNSAcquisition of ARR
15th Dec 20103:42 pmRNSNotification of interest
9th Dec 20107:00 amRNSAcquisition of interest in IDC
30th Nov 20107:00 amRNSOperational Update
22nd Nov 201011:02 amRNSDirector Dealings
19th Nov 20101:16 pmRNSAppointment of Director
10th Nov 20107:00 amRNSHeads of Agreement Signed
1st Nov 20107:00 amRNSAdmission to AIM
5th Jun 200810:59 amRNSCourt Approval of the Reducti
3rd Jun 200811:55 amRNSCourt Approval of Scheme
3rd Jun 20087:00 amRNSSuspension - Premier Research
29th May 20088:26 amRNSHolding(s) in Company
29th May 20088:20 amRNSHolding(s) in Company
28th May 200810:47 amRNSRule 8.3- PREMIER RESEARCH GR
22nd May 200811:18 amRNSRule 8.3-Premier Research Gro
21st May 20083:18 pmRNSHolding(s) in Company
20th May 20082:13 pmRNSRule 8.3- Premier Research Gr
20th May 200811:27 amRNSRule 8.3- Premier Research Gr
20th May 20088:09 amRNSEPT Disclosure
19th May 20084:55 pmRNSHolding(s) in Company
19th May 20084:48 pmRNSHolding(s) in Company
19th May 20084:47 pmRNSHolding(s) in Company
19th May 200812:36 pmRNSRule 8.3- Premier Research Gr
16th May 20089:29 amRNSEPT Disclosure
15th May 200812:25 pmRNSRule 8.3- Premier Research
14th May 200812:28 pmRNSRule 8.3- Premier Research
13th May 20087:46 amRNSEPT Disclosure
8th May 20081:03 pmBUSRule 8.3 - Premier Research Group PLC
8th May 200812:10 pmRNSRule 8.3- Premier Research Gr
8th May 20088:43 amRNSEPT Disclosure
7th May 200812:18 pmRNSResult of EGM
7th May 200810:20 amRNSEPT Disclosure
6th May 20083:20 pmRNSHolding(s) in Company
6th May 20088:33 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.